Showing results (31-40 of 2,355) with videos related to
Sort By:
Pageof 236
Clinical Neuropharmacology|October 1, 1994
Perceived exertion and muscle efficiency in Parkinson's disease: L-DOPA effectsP A LeWitt, A Bharucha, I Chitrit, et al.Clinical Neuropharmacology|October 1, 1994
Double-blind trial of flumazenil in hemiballismusJ Kulisevsky, A Avila, M L Berthier, et al.Clinical Neuropharmacology|August 1, 1997
Irreversible lithium neurotoxicity: an overviewB Kores, M H LaderClinical Neuropharmacology|August 1, 1997
Treatment of Alzheimer's disease with sabeluzole: functional and structural correlatesE Mohr, N P Nair, M Sampson, et al.Clinical Neuropharmacology|June 9, 1998
Pharmacology of pramipexole, a dopamine D3-preferring agonist useful in treating Parkinson's diseaseM F PierceyClinical Neuropharmacology|June 9, 1998
The safety of ropinirole, a selective nonergoline dopamine agonist, in patients with Parkinson's diseaseA E Schrag, D J Brooks, E Brunt, et al.Clinical Neuropharmacology|June 9, 1998
Biophysical membrane interactions of steroid hormones: a potential complementary mechanism of steroid actionG A Golden, P E Mason, R T Rubin, et al.Clinical Neuropharmacology|June 9, 1998
Hemifacial spasm triggered by vasodilatorsF Micheli, M C Scorticati, I Radi Orueta, et al.Clinical Neuropharmacology|July 21, 2016
Comparison of Selegiline and Rasagiline Therapies in Parkinson Disease: A Real-life StudyChava Peretz, Hagar Segev, Violet Rozani, et al.Clinical Neuropharmacology|December 1, 1993
Regional differences in rat brain dopamine transporter binding: function of time after chronic cocaineA Hitri, R J WyattPageof 236